Search

Ecallantide

By reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … Hereditary angioedema is a rare autosomal dominant disorder with mutations to C1-esterase-inhibitor (C1-INH) located on Chromosome 11q, resulting in substantially lower levels of C4 and C1-INH activity

Dostarlimab

[L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair

Zinc phenolsulfonate

Enmetazobactam

[A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.

Elivaldogene autotemcel

It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy,[L39491] an X-linked genetic disorder characterized by missing or non-functional … [A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs.

Human botulinum neurotoxin A/B immune globulin

[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … [L39834] It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma

Perfluorohexyloctane

[A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536] … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.

Felodipine

It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction.

Dexchlorpheniramine

It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells. … The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions.

Brinzolamide

[A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate. … Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma.